---
figid: PMC4134689__nihms600164f2
figtitle: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
  include inhibition of RAS transcription by RNA interference and blockade of posttranslational
  modification by farnesyltransferase inhibitors'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4134689
filename: nihms600164f2.jpg
figlink: /pmc/articles/PMC4134689/figure/F2/
number: F2
caption: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
  include inhibition of RAS transcription by RNA interference and blockade of posttranslational
  modification by farnesyltransferase inhibitors. Agents that block downstream mitogen-activated
  protein kinase (MAPK) signaling include inhibitors of MAPK/ERK kinase (MEK) and
  extracellular signal–regulated kinase (ERK) as well as paradox-breaker RAF inhibitors.
  Agents targeting cell cycle regulation and the phosphoinositide 3-kinase (PI3K)–AKT
  pathway are also being evaluated in combination with MAPK pathway inhibitors. CDK,
  cyclin-dependent kinase; mTOR, mammalian target of rapamycin; Rb, retinoblastoma.'
papertitle: 'Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous
  Leukemia.'
reftext: Douglas B. Johnson, et al. Clin Cancer Res. ;20(16):4186-4192.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7791104
figid_alias: PMC4134689__F2
figtype: Figure
redirect_from: /figures/PMC4134689__F2
ndex: 1971ca89-df10-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4134689__nihms600164f2.html
  '@type': Dataset
  description: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
    include inhibition of RAS transcription by RNA interference and blockade of posttranslational
    modification by farnesyltransferase inhibitors. Agents that block downstream mitogen-activated
    protein kinase (MAPK) signaling include inhibitors of MAPK/ERK kinase (MEK) and
    extracellular signal–regulated kinase (ERK) as well as paradox-breaker RAF inhibitors.
    Agents targeting cell cycle regulation and the phosphoinositide 3-kinase (PI3K)–AKT
    pathway are also being evaluated in combination with MAPK pathway inhibitors.
    CDK, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; Rb, retinoblastoma.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Dsor1
  - Mtk
  - Akt
  - Pten
  - Cdk4
  - Erk7
  - rl
  - Mtor
  - Tor
  - rb
  - CycE
  - cyc
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - CDKN2A
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - CDK4
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - GSK2141795
  - GDC-0941
  - Trametinib
  - Buparlisib
  - Cobimetinib
  - AZD5363
  - Binimetinib
  - Cancer
  - Lung cancer
---
